Zdrowie i gospodarka · 09/08/2017

FDA to Host Public Meeting on Benefit-Risk Assessments in Drug Regulatory Decision-Making

The FDA is requesting public comments on its approach to structured benefit-risk assessments in drug regulatory decision-making, following a series of presentations and discussions with industry experts and patient advocates.